Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $795

Benzinga Newsdesk www.benzinga.com Positive 81.6%

Neg 0% Neu 0% Pos 81.6%

Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $750 to $795.